References
- Brunner H R, Nussberger J, Waeber B. Effects of angiotensin converting enzyme inhibition; A clinical point of view. J Cardiovasc Pharmacol 1985; 7(Suppl.4)73–81
- Turini G A, Waeber B, Brunner H R. The renin angiotensin system in refractory heart failure: Clinical, hemodynamic and hormonal effects of captopril and enalapril. Eur J Cardiol 1983; 4(Suppl. A)189–197
- Biollaz J, Waeber B, Brunner H R. Hypertensive crisis treated with orally administered captopril. Eur J Clin Pharmacol 1983; 25: 145–149
- Tift C P, Gavras H, Kershaw G R, Gavras I, Brunner H R, Liang C S, Chobanian A V. Converting enzyme inhibition in hypertensive emergencies. Ann Intern Med 1979; 90: 43–47
- DiPette D J, Ferraro J C, Evans R R, Martin M. Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises. Clin Pharmacol Ther 1985; 38: 199–204
- Ondetti M A, Williams N J, Sabo E F, Pluscec J, Weaver E R, Kocy O. Angiotensin converting enzyme inhibitors from the venom of Bothrops jararaca: isolation, elucidation of structure and synthesis. Biochemistry 1971; 19: 4033–4039
- Brunner H R, Nussberger J, Waeber B. The present molecules of converting enzyme inhibitors. J Cardiovasc Pharmacol 1985; 7(Suppl.1)2–11
- Chen D S, Brunner H R, Waeber B. In vitro response of plasma angiotensin converting enzyme to precursors and active forms of converting enzyme inhibitors. Curr Ther Res 1984; 35: 253–262
- Nussberger J, Brunner D B, Waeber B, Brunner H R. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985, Suppl.I: 1–7